INOVIO PHARMACEUTICALS, INC. Investment Income, Interest
INOVIO PHARMACEUTICALS, INC. (INO) reported Investment Income, Interest of $363.85 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-06-30 was $363.85K, a 40.42% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-03-31 was $439.59K, a 45.60% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-12-31 was $449.34K, a 47.30% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-09-30 was $552.11K, a 50.11% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for fiscal 2025 was $2.42M, a 49.23% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for fiscal 2024 was $4.77M, a 41.39% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. investment income, interest for fiscal 2023 was $8.13M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $363.85K 10-Q · filed 2026-08-12 | $803.44K 10-Q · filed 2026-08-12 | $1.25M derived: sum of 3 quarters · filed 2026-08-12 | $1.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $439.59K 10-Q · filed 2026-05-13 | $888.93K derived: sum of 2 quarters · filed 2026-05-13 | $1.44M derived: sum of 3 quarters · filed 2026-05-13 | $2.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $449.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.00M derived: sum of 2 quarters · filed 2026-03-12 | $1.61M derived: sum of 3 quarters · filed 2026-08-12 | $2.42M 10-K · filed 2026-03-12 |
| 2025-09-30 | $552.11K 10-Q · filed 2025-11-10 | $1.16M derived: sum of 2 quarters · filed 2026-08-12 | $1.97M 10-Q · filed 2025-11-10 | $2.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $610.64K 10-Q · filed 2026-08-12 | $1.42M 10-Q · filed 2026-08-12 | $2.27M derived: sum of 3 quarters · filed 2026-08-12 | $3.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $808.08K 10-Q · filed 2026-05-13 | $1.66M derived: sum of 2 quarters · filed 2026-05-13 | $2.77M derived: sum of 3 quarters · filed 2026-05-13 | $4.07M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $852.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.96M derived: sum of 2 quarters · filed 2026-03-12 | $3.27M derived: sum of 3 quarters · filed 2026-03-12 | $4.77M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.11M 10-Q · filed 2025-11-10 | $2.41M derived: sum of 2 quarters · filed 2025-11-10 | $3.91M 10-Q · filed 2025-11-10 | $5.73M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.31M 10-Q · filed 2025-08-12 | $2.81M 10-Q · filed 2025-08-12 | $4.63M derived: sum of 3 quarters · filed 2025-08-12 | $6.57M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.50M 10-Q · filed 2025-05-13 | $3.32M derived: sum of 2 quarters · filed 2025-05-13 | $5.26M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $3.76M derived: sum of 2 quarters · filed 2025-03-18 | $8.13M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $1.94M 10-Q · filed 2024-11-14 | $6.31M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |